During the past decade, Innovative Clinical Research Institute conducted 69 clinical trials. In the 10-year time frame, 69 clinical trials started and 29 clinical trials were completed, i.e. on average, 42% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 22 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Innovative Clinical Research Institute" #1 sponsor was "Celgene" with 5 trials, followed by "Gilead Sciences" with 5 trials sponsored, "Amgen" with 4 trials sponsored, "Incyte Corporation" with 4 trials sponsored and "Daiichi Sankyo, Inc." with 4 trials sponsored. Other sponsors include 52 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Innovative Clinical Research Institute" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Innovative Clinical Research Institute" are "Breast Cancer" (8 trials), "Gastric Cancer" (5 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Colorectal Cancer" (4 trials) and "Lung Cancer" (4 trials). Many other conditions were trialed in "Innovative Clinical Research Institute" in a lesser frequency.

Most popular intervention types in "Innovative Clinical Research Institute" are "Drug" (72 trials), "Biological" (8 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Docetaxel" (5 trials), "Pembrolizumab" (5 trials), "Bemarituzumab" (4 trials) and "Carboplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Innovative Clinical Research Institute" are 74 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Innovative Clinical Research Institute". undefined are not yet recruiting, 25 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Innovative Clinical Research Institute, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Innovative Clinical Research Institute, 16 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".